Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial

by Adjei, A.A, Aggarwal, C., Antonia, S., Arnaldez, F.I, Atkinson, V., Baughman, J., Birnbaum, A., Bonvini, E., Cavallo, R., Cohen, R.B, Ferris, R.L, Ganju, V., Goldberg, S.M, Hauke, R., Joshua, A.M, Kalebasty, A.R, Kaul, S., Lakhani, N.J, Lou, Y., Moore, P.A, P Zandberg, D., Peng, L., Prawira, A., Rahma, O., Seetharam, M., Tolcher, A., Vogelzang, N., Weickhardt, A., Zhang, X.
Published 2022